Cargando…
Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
To investigate the exposure–safety relationships of afatinib in Japanese population, we performed population pharmacokinetics (PK) analysis of afatinib in Japanese advanced non-small cell lung cancer patients harboring epidermal growth factor receptor mutation. Plasma samples were collected at 0.5–1...
Autores principales: | Nakao, Keiko, Kobuchi, Shinji, Marutani, Shuhei, Iwazaki, Ayano, Tamiya, Akihiro, Isa, Shunichi, Okishio, Kyoichi, Kanazu, Masaki, Tamiya, Motohiro, Hirashima, Tomonori, Imai, Kimie, Sakaeda, Toshiyuki, Atagi, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890782/ https://www.ncbi.nlm.nih.gov/pubmed/31796841 http://dx.doi.org/10.1038/s41598-019-54804-9 |
Ejemplares similares
-
Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis
por: Naito, Yujiro, et al.
Publicado: (2017) -
The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021) -
Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status
por: Adachi, Yuichi, et al.
Publicado: (2019) -
Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020) -
Retrospective analysis of long‐term survival factors in patients with advanced non‐small cell lung cancer treated with nivolumab
por: Murakami, Yusuke, et al.
Publicado: (2022)